Literature DB >> 27509881

Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer.

Milou H Martens1, Monique Maas1, Luc A Heijnen1, Doenja M J Lambregts1, Jeroen W A Leijtens1, Laurents P S Stassen1, Stephanie O Breukink1, Christiaan Hoff1, Eric J Belgers1, Jarno Melenhorst1, Rob Jansen1, Jeroen Buijsen1, Ton G M Hoofwijk1, Regina G H Beets-Tan1, Geerard L Beets2.   

Abstract

BACKGROUND: The aim of this study was to establish the oncological and functional results of organ preservation with a watch-and-wait approach (W&W) and selective transanal endoscopic microsurgery (TEM) in patients with a clinical complete or near-complete response (cCR) after neoadjuvant chemoradiation for rectal cancer.
METHODS: Between 2004 and 2014, organ preservation was offered if response assessment with digital rectal examination, endoscopy, and MRI showed (near) cCR. Watch-and-wait was offered for cCR, and two options were offered for near cCR: TEM or reassessment after three months. Follow-up included endoscopy and MRIs every three months during the first year, and every six months thereafter. Long-term outcome was assessed with Kaplan-Meier curves. Functional outcome was assessed with colostomy-free survival and Vaizey incontinence score (0 = perfect continence, 24 = totally incontinent).
RESULTS: One hundred patients were included, with median follow-up of 41.1 months. Sixty-one had cCR at initial response assessment. Thirty-nine had near cCR, of whom 24 developed cCR at the second assessment and 15 patients underwent TEM (9 ypT0, 1 ypT1, 5 ypT2). Fifteen patients developed a local regrowth (12 luminal, 3 nodal), all salvageable and within 25 months. Five patients developed metastases, and five patients died. Three-year overall survival was 96.6% (95% confidence interval [CI] = 89.9% to 98.9%), distant metastasis-free survival was 96.8% (95% CI = 90.4% to 99.0%), local regrowth-free survival was 84.6% (95% CI = 75.8% to 90.5%), and disease-free survival was 80.6% (95% CI = 70.9% to 87.4%). Colostomy-free survival was 94.8% (95% CI = 88.0% to 97.8%), with a good continence after watch-and-wait (Vaizey = 3.4, SD = 3.9) and moderate after TEM (Vaizey = 9.7, SD = 5.1).
CONCLUSIONS: Organ preservation appears oncologically safe for selected rectal cancer patients with a cCR or near cCR after neoadjuvant chemoradiation when applying strict selection criteria and frequent follow-up, including endoscopy and MRI. The low colostomy rate and the good long-term functional outcome warrant discussing this option with the patient as an alternative to major surgery.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2016        PMID: 27509881     DOI: 10.1093/jnci/djw171

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  66 in total

Review 1.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

Review 2.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 3.  [Evidence-based surgery of rectal cancer].

Authors:  M Grade; H Flebbe; B M Ghadimi
Journal:  Chirurg       Date:  2019-05       Impact factor: 0.955

4.  Diffusion-weighted MRI to assess response to chemoradiotherapy in rectal cancer: main interpretation pitfalls and their use for teaching.

Authors:  Doenja M J Lambregts; Miriam M van Heeswijk; Andrea Delli Pizzi; Saskia G C van Elderen; Luisa Andrade; Nicky H G M Peters; Peter A M Kint; Margreet Osinga-de Jong; Shandra Bipat; Rik Ooms; Max J Lahaye; Monique Maas; Geerard L Beets; Frans C H Bakers; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2017-04-13       Impact factor: 5.315

5.  The good, the bad and the ugly: rectal cancers in the twenty-first century.

Authors:  G P São Julião; A Habr-Gama; B B Vailati; R O Perez
Journal:  Tech Coloproctol       Date:  2017-06-19       Impact factor: 3.781

6.  Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

Authors:  C A Kim; S Ahmed; S Ahmed; B Brunet; H Chalchal; R Deobald; C Doll; M P Dupre; V Gordon; R M Lee-Ying; H Lim; D Liu; J M Loree; J P McGhie; K Mulder; J Park; B Yip; R P Wong; A Zaidi
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

7.  Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study.

Authors:  A Barina; A De Paoli; P Delrio; M Guerrieri; A Muratore; F Bianco; D Vespa; C Asteria; E Morpurgo; A Restivo; C Coco; U Pace; C Belluco; C Aschele; S Lonardi; V Valentini; G Mantello; I Maretto; P Del Bianco; A Perin; S Pucciarelli
Journal:  Tech Coloproctol       Date:  2017-07-28       Impact factor: 3.781

8.  Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.

Authors:  Steven N Seyedin; M M Hasibuzzaman; Vivan Pham; Michael S Petronek; Cameron Callaghan; Amanda L Kalen; Kranti A Mapuskar; Sarah L Mott; Douglas R Spitz; Bryan G Allen; Joseph M Caster
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-02-06       Impact factor: 7.038

Review 9.  Selective use of radiation for locally advanced rectal cancer: one size does not fit all.

Authors:  Campbell S Roxburgh; Martin R Weiser
Journal:  Minerva Chir       Date:  2018-05-25       Impact factor: 1.000

Review 10.  Current Status of the Management of Stage I Rectal Cancer.

Authors:  Craig Howard Olson
Journal:  Curr Oncol Rep       Date:  2020-04-02       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.